This webcast features: James Humphrey, research and technology specialist, Garima Sinha, lead applications scientist, & Jessica Santa Maria, technical marketing lead, Croda Pharma.
Poloxamer 188 is a surfactant with a longstanding history of use in pharmaceutical drugs, spanning dosage routes from oral to topical and parenteral administration. In the biomanufacturing space, it finds application not only as a surfactant for parenteral biological formulations, but also in cell culture as a shear stress protectant.
Its specific surfactant properties make it effective at stabilizing proteins, as well as protecting cells from shear stress caused by agitation in a bioreactor. Poloxamer 188 has the ability to prevent cell shear stress due to its specific balance of hydrophobic PPO chain flanked by two blocks of hydrophilic PEO. However, impurities from the manufacturing process can compromise its performance, leading to detrimental effects on cell health and contributing to batch-batch inconsistency.
One persistent challenge in the market has been the search for reliable manufacturers of poloxamer 188 with the ability to produce consistent materials exhibiting consistent batch-to-batch performance, with dependable outcomes in biomanufacturing processes. This challenge has led to the development of Super Refined™ Poloxamer 188, which our presenters will share more about in this webinar.
Optimized specifically for mammalian cell culture, Super Refined™ Poloxamer 188 offers excellent cell culture performance, with highly controlled impurity profiles that de-risk variable cell performance from batch-to-batch. We will demonstrate exceptional performance in cell viability performance against competitor materials in both CHO and HEK suspension lines, present data highlighting batch-to-batch consistency in performance along with supporting analytical data on the poloxamer compositional and impurity profile.
Register or Login and hit Watch on Demand to view the recorded webcast now.